AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1307904 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Bar (n = 21)
Number of subjects: 62
Study 1307904 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (n = 22)
Number of subjects: 62
Study 1307904 — intervention group
Group type: COMPARATOR
Intervention: Synchronized Intermittent Mandatory Ventilation (n = 19)
Number of subjects: 62
Study 6094655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 48
Study 6094655 — intervention group
Group type: COMPARATOR
Intervention: Conventional antiulcer agents (Control)
Number of subjects: 48
Study 31492797 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE risk score and associated treatment recommendations
Number of subjects: 3000
Study 31492797 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 3000
Study 30005312 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite Heart Health Improvement Project (WHHIP)
Number of subjects: 98
Study 26717958 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent health behavior changes and feeding practices
Number of subjects: 590
Study 26717958 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater parental monitoring
Number of subjects: 590
Study 23306715 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group (ropivacaine, dexamethasone, isepamicin)
Number of subjects: 40
Study 23306715 — intervention group
Group type: COMPARATOR
Intervention: Control group (ropivacaine, isepamicin)
Number of subjects: 40
Study 23306715 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group
Number of subjects: 40
Study 23306715 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 20523113 — intervention group
Group type: EXPERIMENTAL
Intervention: HB‐AS02 vaccine (0 and 1 month)
Number of subjects: 450
Study 16322166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation consultant intervention (2 prenatal meetings, postpartum hospital visit, home visits, and telephone calls)
Number of subjects: 304
Study 16322166 — intervention group
Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 304
Study 11748388 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 8
Study 11748388 — intervention group
Group type: EXPERIMENTAL
Intervention: M6G
Number of subjects: 8
Study 9504193 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine Clonixinate (LC) 125 mg
Number of subjects: 131
Study 9504193 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 500 mg + Codeine 30 mg
Number of subjects: 131
Study 8306757 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-mg transdermal nicotine therapy with group counseling for 8 weeks (study 1)
Number of subjects: 200
Study 8306757 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-mg transdermal nicotine therapy for 4 weeks followed by 11-mg for 2 weeks with brief individual counseling (study 2)
Number of subjects: 200
Study 8306757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 3179052 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic fluid
Number of subjects: 0
Study 3179052 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate
Number of subjects: 0
Study 3179052 — intervention group
Group type: COMPARATOR
Intervention: Hydroxypropylmethylcellulose (HPMC)
Number of subjects: 0
Study 12858225 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% climbazole
Number of subjects: 10
Study 29847967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (1 μg/kg)
Number of subjects: 90
Study 29847967 — intervention group
Group type: COMPARATOR
Intervention: Intranasal saline, intravenous saline and propofol (group P)
Number of subjects: 90
Study 29847967 — intervention group
Group type: COMPARATOR
Intervention: Intranasal saline, intravenous sulfentanil and propofol (group SP)
Number of subjects: 90
Study 26081140 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenoside Rd
Number of subjects: 589
Study 25519844 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored biopsychosocial intervention for 10 weeks
Number of subjects: 0
Study 25519844 — intervention group
Group type: COMPARATOR
Intervention: Usual care for 10 weeks
Number of subjects: 0
Study 22314873 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (n=28)
Number of subjects: 55
Study 22314873 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (n=27)
Number of subjects: 55
Study 20579522 — intervention group
Group type: EXPERIMENTAL
Intervention: Satiereal (176.5 mg extract per day, n = 31)
Number of subjects: 60
Study 20579522 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 60
Study 18566196 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg po (Group G)
Number of subjects: 51
Study 18566196 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 51
Study 15898938 — intervention group
Group type: EXPERIMENTAL
Intervention: DBX paste
Number of subjects: 60
Study 15898938 — intervention group
Group type: EXPERIMENTAL
Intervention: DBX putty
Number of subjects: 60
Study 15898938 — intervention group
Group type: COMPARATOR
Intervention: DFDBA (control)
Number of subjects: 60
Study 12757969 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) 150 mg/day
Number of subjects: 160
Study 12757969 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 160
Study 12757969 — intervention group
Group type: EXPERIMENTAL
Intervention: DMI + CM
Number of subjects: 160
Study 12757969 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Non-contingent voucher control
Number of subjects: 160
Study 10680303 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (500 micrograms/kg loading dose followed by 100 micrograms/kg/h infusion)
Number of subjects: 60
Study 10680303 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (0.15 mg/kg loading dose followed by 5 mg/h infusion)
Number of subjects: 60
Study 10680303 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 60
Study 10680303 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 60
Study 8768490 — intervention group
Group type: EXPERIMENTAL
Intervention: Training interventions aimed at supporting perceptual and pattern-recognition activities in dynamic environments
Number of subjects: 0
Study 8768490 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 1817959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (100, 200, and 300 mg/day, b.i.d. regimen)
Number of subjects: 11
Study 1817959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7104913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasally administered phenylephrine (doses from 0.5 to 4 mg, total 7.5 to 15 mg)
Number of subjects: 26
Study 7104913 — intervention group
Group type: COMPARATOR
Intervention: Placebo of identical appearance
Number of subjects: 26
Study 31122926 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational attainment (each additional standard deviation of education, 3.6 years)
Number of subjects: 0
Study 31122926 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 0
Study 31122926 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 0
Study 31122926 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking behaviour
Number of subjects: 0
Study 31122926 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined risk factors (BMI, systolic blood pressure, smoking behaviour)
Number of subjects: 0
Study 31122926 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational attainment
Number of subjects: 0
Study 29510699 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically active academic lessons (2 x 45 minutes weekly for 10 months)
Number of subjects: 30
Study 29510699 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically active academic lessons
Number of subjects: 30
Study 29510699 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators for implementation
Number of subjects: 30
Study 29510699 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers for implementation
Number of subjects: 30
Study 26933094 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral opioid treatment
Number of subjects: 31
Study 24916953 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital decision system allowing ambulance nurses to transport older adults directly to geriatric care at a community‐based hospital (CH)
Number of subjects: 806
Study 24916953 — intervention group
Group type: COMPARATOR
Intervention: Control group transported to the emergency department (ED)
Number of subjects: 806
Study 23190932 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional exercise class (twice weekly for six weeks from week 12 to week 18 post surgery) supervised by a chartered Physiotherapist
Number of subjects: 70
Study 23190932 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 70
Study 20709000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal TIV (15 μg HA per strain)
Number of subjects: 62
Study 20709000 — intervention group
Group type: COMPARATOR
Intervention: Conventional TIV (15 μg HA per strain)
Number of subjects: 62
Study 16903003 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified multivariate Cox regression model
Number of subjects: 0
Study 16903003 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival time approach for analyzing AEs
Number of subjects: 0
Study 16382423 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive-behavior therapy (IT condition)
Number of subjects: 40
Study 16382423 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (DT condition)
Number of subjects: 40
Study 11916777 — intervention group
Group type: EXPERIMENTAL
Intervention: PFC (perflubron emulsion)
Number of subjects: 9
Study 11916777 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 9
Study 9857664 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 22
Study 9857664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7611746 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 ppm capsaicin
Number of subjects: 0
Study 7611746 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 ppm capsaicin
Number of subjects: 0
Study 7611746 — intervention group
Group type: COMPARATOR
Intervention: vehicle food
Number of subjects: 0
Study 7611746 — intervention group
Group type: COMPARATOR
Intervention: non-chilli flavoured food
Number of subjects: 0
Study 7611746 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 ppm capsaicin in tomato juice vehicle
Number of subjects: 0
Study 2375815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution (Rehydralyte) containing 75 mEq/L of Na
Number of subjects: 0
Study 2375815 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluids (Ringer's Lactate and a solution of 56 mEq/L of Na)
Number of subjects: 0
Study 199129 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate and oral fluphenazine
Number of subjects: 0
Study 199129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30907298 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention
Number of subjects: 117
Study 30907298 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study 31449932 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized smoking cessation intervention (brief presentation by a vascular surgeon)
Number of subjects: 59
Study 31449932 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 weeks of free nicotine patches and referral to an outpatient smoking-cessation program)
Number of subjects: 59
Study 31449932 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 59
Study 27477668 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management for 24 hours
Number of subjects: 161
Study 27477668 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management for 48 hours
Number of subjects: 161
Study 25720675 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention for symptom awareness and diabetes knowledge
Number of subjects: 30
Study 25720675 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text messaging)
Number of subjects: 30
Study 23177514 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily for the first 3 weeks of each 4 week cycle
Number of subjects: 760
Study 23177514 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for the first 3 weeks of each 4 week cycle
Number of subjects: 760
Study 23177514 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 760
Study 23177514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760
Study 22332549 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (100 microg initial dose, adjusted by 5 microg intervals) with 0.0625% W/V bupivacaine
Number of subjects: 46
Study 22332549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (20 microg initial dose, adjusted by 1 microg intervals) with 0.0625% W/V bupivacaine
Number of subjects: 46
Study 22332549 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl and Sufentanil with 0.0625% W/V bupivacaine
Number of subjects: 46
Study 19565824 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium levothyroxin and standard hypotensive therapy with ACE inhibitors
Number of subjects: 217
Study 19565824 — intervention group
Group type: COMPARATOR
Intervention: Standard hypotensive therapy with ACE inhibitors
Number of subjects: 217
Study 17014518 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dialysis (2 hr, 6 times weekly for 4 weeks)
Number of subjects: 12
Study 17014518 — intervention group
Group type: COMPARATOR
Intervention: Thrice‐weekly hemodialysis (4 hr for 4 weeks)
Number of subjects: 12
Study 15486373 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - triamcinolone acetonide (1200 microg daily)
Number of subjects: 1116
Study 15486373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1116
Study 15486373 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 1116
Study 11190457 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic guide wire
Number of subjects: 2
Study 11190457 — intervention group
Group type: COMPARATOR
Intervention: Standard guide wire
Number of subjects: 2
Study 9388109 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine administration and femoral sheath removal (group I, n = 117)
Number of subjects: 228
Study 9388109 — intervention group
Group type: COMPARATOR
Intervention: No heparin neutralization and delayed sheath removal (group II, n = 111)
Number of subjects: 228
Study 7956392 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 348
Study 7956392 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 348
Study 7956392 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 348
Study 3113599 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwartz strain live measles vaccine
Number of subjects: 4500
Study 30837416 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.5% ferric sulfate (FS) with zinc oxide‐eugenol (ZOE)
Number of subjects: 29
Study 30837416 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.5% ferric sulfate (FS) with calcium hydroxide (CH)
Number of subjects: 29
Study 30837416 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25% sodium hypochlorite (NaOCl) with zinc oxide‐eugenol (ZOE)
Number of subjects: 29
Study 30837416 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25% sodium hypochlorite (NaOCl) with calcium hydroxide (CH)
Number of subjects: 29
Study 28374931 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori infection
Number of subjects: 200
Study 28374931 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic HP
Number of subjects: 200
Study 28374931 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of HP symptoms
Number of subjects: 200
Study 26597341 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Care Model (GCM)
Number of subjects: 1147
Study 26597341 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1147
Study 25133856 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Training (BT)
Number of subjects: 195
Study 25133856 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 195
Study 22251780 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 79
Study 19004600 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline with phone counseling
Number of subjects: 1018
Study 19004600 — intervention group
Group type: COMPARATOR
Intervention: Varenicline with Web support only
Number of subjects: 1018
Study 19004600 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline users
Number of subjects: 1018
Study 17460178 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype 4 (containing the ‐592A variant allele)
Number of subjects: 0
Study 17460178 — intervention group
Group type: EXPERIMENTAL
Intervention: ‐2849AA carriers
Number of subjects: 0
Study 15541060 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical nurse specialist care managers' activities in the Bipolar Disorders Program (BDP)
Number of subjects: 0
Study 15541060 — intervention group
Group type: EXPERIMENTAL
Intervention: Total clinic time
Number of subjects: 0
Study 10893282 — intervention group
Group type: EXPERIMENTAL
Intervention: SD/01 (30, 100, or 300 microg/kg)
Number of subjects: 13
Study 10893282 — intervention group
Group type: COMPARATOR
Intervention: Daily filgrastim (5 microg/kg/d)
Number of subjects: 13
Study 9372293 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pursuit of moving target
Number of subjects: 0
Study 9372293 — intervention group
Group type: COMPARATOR
Intervention: Fixation on stationary target during moving display
Number of subjects: 0
Study 9372293 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of target exposure (480 ms) with prior fixations
Number of subjects: 0
Study 9372293 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive response after target disappearance
Number of subjects: 0
Study 1388334 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication in patients with DSM‐III melancholia (76 patients)
Number of subjects: 231
Study 1388334 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with DSM‐III melancholia (44 patients)
Number of subjects: 231
Study 1388334 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication in patients without melancholia (76 patients)
Number of subjects: 231
Study 1388334 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients without melancholia (35 patients)
Number of subjects: 231
Study 3903068 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin/dipyridamole combination
Number of subjects: 22
Study 3903068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 3550026 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning therapy (n = 66)
Number of subjects: 121
Study 3550026 — intervention group
Group type: COMPARATOR
Intervention: 3‐month waiting period (n = 55)
Number of subjects: 121
Study 30898169 — intervention group
Group type: EXPERIMENTAL
Intervention: Training package (including videos, simulation, and Q&A sessions)
Number of subjects: 125
Study 27761730 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control (4.4‐6.1 mM)
Number of subjects: 15
Study 27761730 — intervention group
Group type: COMPARATOR
Intervention: Loose glycemic control (6.7‐8.3 mM)
Number of subjects: 15
Study 27761730 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control
Number of subjects: 15
Study 26333022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training program with 49 exercises targeting various cognitive capacities, completed for 15 minutes at least 5 days per week for 10 weeks.
Number of subjects: 4715
Study 26333022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training program
Number of subjects: 4715
Study 26333022 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (crossword puzzles)
Number of subjects: 4715
Study 23886632 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose followed by 75 mg/day)
Number of subjects: 177
Study 21382044 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Muscle Tension (AMT)
Number of subjects: 72
Study 21382044 — intervention group
Group type: COMPARATOR
Intervention: Distraction Control (repeated gentle foot flexions)
Number of subjects: 72
Study 18498993 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) 0.02% (0.2 mg/mL)
Number of subjects: 81
Study 18498993 — intervention group
Group type: COMPARATOR
Intervention: Untreated (no eye treated with MMC)
Number of subjects: 81
Study 16256250 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (400,000 IU)
Number of subjects: 118
Study 16256250 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (300 mg)
Number of subjects: 118
Study 16256250 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A + Zinc supplementation
Number of subjects: 118
Study 16256250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 12655320 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 1.4 g/kg
Number of subjects: 48
Study 12655320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10706042 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir 800 mg four times daily for 120 days (ACV)
Number of subjects: 0
Study 10706042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir 5 mg/kg every 12 h for 14 days followed by ACV for 106 days (GCV)
Number of subjects: 0
Study 10706042 — intervention group
Group type: COMPARATOR
Intervention: CMV disease
Number of subjects: 0
Study 10706042 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic CMV infection
Number of subjects: 0